613 related articles for article (PubMed ID: 20843473)
1. Resistance to polymyxins: Mechanisms, frequency and treatment options.
Falagas ME; Rafailidis PI; Matthaiou DK
Drug Resist Updat; 2010; 13(4-5):132-8. PubMed ID: 20843473
[TBL] [Abstract][Full Text] [Related]
2. Polymyxins and their novel derivatives.
Vaara M
Curr Opin Microbiol; 2010 Oct; 13(5):574-81. PubMed ID: 20869908
[TBL] [Abstract][Full Text] [Related]
3. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
Brown P; Dawson MJ
J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
[TBL] [Abstract][Full Text] [Related]
4. PhoP-regulated Salmonella resistance to the antimicrobial peptides magainin 2 and polymyxin B.
Shi Y; Cromie MJ; Hsu FF; Turk J; Groisman EA
Mol Microbiol; 2004 Jul; 53(1):229-41. PubMed ID: 15225317
[TBL] [Abstract][Full Text] [Related]
5. Emergence of polymyxin resistance in Gram-negative bacteria.
Olaitan AO; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):581-582. PubMed ID: 27939183
[No Abstract] [Full Text] [Related]
6. The current state of multidrug-resistant gram-negative bacilli in North America.
Nicasio AM; Kuti JL; Nicolau DP
Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
[TBL] [Abstract][Full Text] [Related]
7. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
Falagas ME; Kasiakou SK
Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
[TBL] [Abstract][Full Text] [Related]
8. Release of the lipopolysaccharide deacylase PagL from latency compensates for a lack of lipopolysaccharide aminoarabinose modification-dependent resistance to the antimicrobial peptide polymyxin B in Salmonella enterica.
Kawasaki K; China K; Nishijima M
J Bacteriol; 2007 Jul; 189(13):4911-9. PubMed ID: 17483225
[TBL] [Abstract][Full Text] [Related]
9. Polymyxins: a review of the current status including recent developments.
Kwa AL; Tam VH; Falagas ME
Ann Acad Med Singap; 2008 Oct; 37(10):870-83. PubMed ID: 19037522
[TBL] [Abstract][Full Text] [Related]
10. New information about the polymyxin/colistin class of antibiotics.
Molina J; Cordero E; Pachón J
Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
[TBL] [Abstract][Full Text] [Related]
11. The pmrF polymyxin-resistance operon of Yersinia pseudotuberculosis is upregulated by the PhoP-PhoQ two-component system but not by PmrA-PmrB, and is not required for virulence.
Marceau M; Sebbane F; Ewann F; Collyn F; Lindner B; Campos MA; Bengoechea JA; Simonet M
Microbiology (Reading); 2004 Dec; 150(Pt 12):3947-57. PubMed ID: 15583148
[TBL] [Abstract][Full Text] [Related]
12. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.
Poirel L; Jayol A; Nordmann P
Clin Microbiol Rev; 2017 Apr; 30(2):557-596. PubMed ID: 28275006
[TBL] [Abstract][Full Text] [Related]
13. First structure of the polymyxin resistance proteins.
Fu W; Yang F; Kang X; Zhang X; Li Y; Xia B; Jin C
Biochem Biophys Res Commun; 2007 Oct; 361(4):1033-7. PubMed ID: 17686460
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of polymyxin resistance: knowns and unknowns.
Baron S; Hadjadj L; Rolain JM; Olaitan AO
Int J Antimicrob Agents; 2016 Dec; 48(6):583-591. PubMed ID: 27524102
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
Vergidis PI; Falagas ME
Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
[TBL] [Abstract][Full Text] [Related]
17. Is it time to move away from polymyxins?: evidence and alternatives.
Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B
Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595
[TBL] [Abstract][Full Text] [Related]
18. Will new antimicrobials overcome resistance among Gram-negatives?
Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
[TBL] [Abstract][Full Text] [Related]
19. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
Falagas ME; Bliziotis IA
Int J Antimicrob Agents; 2007 Jun; 29(6):630-6. PubMed ID: 17306965
[TBL] [Abstract][Full Text] [Related]
20. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
Falagas ME; Kasiakou SK
Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
